Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing and commercializing therapies for significant unmet medical needs, with an initial emphasis on kidney disease. The company’s business model is to in-license drug technologies, advance them through development and regulatory review, and then commercialize or partner the assets in global markets.

2.59

2.59

— Unicycive Therapeutics, Inc.
%
Lead kidney disease program70% Development and regulatory advancement of OLC and related kidney-disease therapies.
Licensed development assets20% In-licensed technologies and drug candidates acquired for further development.
Collaboration and licensing revenue10% Potential revenue from partnering, licensing, and related agreements.

Unicycive’s direct customers are not traditional end-market buyers today; its current economic counterparties are...

  • Regulatory authoritiesprimary

    The FDA and other agencies review clinical, manufacturing, and safety data for approval.

  • Biopharmaceutical partnersprimary

    Potential licensees or collaborators for ex-U.S. commercialization and development support.

  • Nephrology clinicianssecondary

    Physicians who would prescribe approved kidney-disease therapies.

  • Kidney disease patientssecondary

    Patients who would ultimately receive the company’s approved treatments.

Unicycive is headquartered in the United States and focuses first on U.S. regulatory approval for its product...

  • •Headquartered in the United States
  • •Initial regulatory focus is U.S. approval
  • •Global partnering model for non-U.S. markets
  • •Operations are centered on development and regulatory work

The company’s strategy is to advance in-licensed assets through a streamlined development platform, with kidney disease...

01
Complete FDA resubmission and approval path for OLCshort-term

Regulatory clearance is the key step to convert the lead asset into a commercial product.

02
Build a partner-led global commercialization modelmedium-term

Partnerships can extend reach without building a large international sales force.

03
Expand the pipeline beyond the initial kidney focuslong-term

A broader pipeline reduces dependence on a single asset and therapeutic area.

Unicycive faces the typical risks of a clinical-stage biotech company: regulatory setbacks, manufacturing compliance...

high

FDA approval and resubmission risk for OLC

The lead program depends on resolving regulatory deficiencies and obtaining approval.

Scope
Oxylanthanum Carbonate (OLC)
Materiality
high
high

Third-party manufacturing vendor compliance risk

The CRL cited a compliance issue at a third-party manufacturer, showing reliance on external CMC execution.

Scope
Manufacturing and supply chain
Materiality
high
medium

Pipeline concentration risk

The company has a limited number of programs, so setbacks are not easily offset.

Scope
Single-asset and early pipeline concentration
Materiality
high
medium

Financing and dilution risk

Clinical-stage development typically requires repeated capital raises before product revenue is established.

Scope
Equity financing and preferred stock structures
Materiality
high
Revenue recognition under ASC 606
Can shift revenue between periods and affect comparability
Warrant liability fair value
Can create earnings volatility unrelated to operations
Mezzanine equity classification for preferred stock
Affects balance sheet presentation and equity analysis
Research and development expense timing
Early-stage development spending drives reported losses and cash burn

Ultragenyx Pharmaceutical Inc.

RARE · Pharmaceutical Preparations

Theriva Biologics, Inc.

TOVX · Pharmaceutical Preparations

GENELUX Corp

GNLX · Pharmaceutical Preparations

uniQure N.V.

QURE · Pharmaceutical Preparations

EXICURE, INC.

XCUR · Pharmaceutical Preparations

INOVIO PHARMACEUTICALS, INC.

INO · Pharmaceutical Preparations

: 29/04/2026